UMRS 1018, 16av. Paul Vaillant Couturier, 94807 Villejuif Cédex, France. 3 INSERM U1147, Univ Paris Sorbonne Cité UMRS Polyclinique Saint Privat Clinique Beau Soleil, vol.775, issue.4 6 7 9 10 ,
Projections de l'incidence et de la mortalité par cancer en France en 2011. Rapport technique. Saint-Maurice: Institut de veille sanitaire, 2011. ,
International trends and patterns of prostate cancer incidence and mortality, International Journal of Cancer, vol.85, issue.1, pp.60-67, 2000. ,
DOI : 10.1002/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO;2-B
Human prostate cancer risk factors, Cancer, vol.17, issue.S10, pp.2371-2490, 2004. ,
DOI : 10.1002/cncr.20408
Table of Contents, Front Biosci, vol.11, pp.1388-1413, 2006. ,
DOI : 10.3726/978-1-4539-1214-0/3
Trends and Patterns of Prostate Cancer: What Do They Suggest?, Epidemiologic Reviews, vol.23, issue.1, pp.3-13, 2001. ,
DOI : 10.1093/oxfordjournals.epirev.a000792
Obesity, metabolic syndrome, and prostate cancer, Am J Clin Nutr, vol.86, pp.843-857, 2007. ,
Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea, Cancer Control, vol.14, pp.78-85, 2007. ,
Considerations of circadian impact for defining 'shift work' in cancer studies: IARC Working Group Report, cancer studies: IARC Working Group Report, pp.154-162, 2011. ,
DOI : 10.1136/oem.2009.053512
Nightshift work and risk of breast cancer and other cancers???a critical review of the epidemiologic evidence, Scandinavian Journal of Work, Environment & Health, vol.34, issue.1, pp.5-22, 2008. ,
DOI : 10.5271/sjweh.1194
Shift work and cancer ??? considerations on rationale, mechanisms, and epidemiology, Scandinavian Journal of Work, Environment & Health, vol.36, issue.2, pp.163-179, 2010. ,
DOI : 10.5271/sjweh.2899
Hypotheses for mechanisms linking shiftwork and cancer, Medical Hypotheses, vol.77, issue.3, pp.430-436, 2011. ,
DOI : 10.1016/j.mehy.2011.06.002
Circadian Disruption, Sleep Loss, and Prostate Cancer Risk: A Systematic Review of Epidemiologic Studies, Cancer Epidemiology Biomarkers & Prevention, vol.21, issue.7, pp.1002-1011, 2012. ,
DOI : 10.1158/1055-9965.EPI-12-0116
Prospective Cohort Study of the Risk of Prostate Cancer among Rotating-Shift Workers: Findings from the Japan Collaborative Cohort Study, American Journal of Epidemiology, vol.164, issue.6, pp.549-555, 2006. ,
DOI : 10.1093/aje/kwj232
Rotating Shift Work and Risk of Prostate Cancer, Epidemiology, vol.18, issue.1, pp.182-183, 2007. ,
DOI : 10.1097/01.ede.0000249519.33978.31
Industry-based retrospective cohort study of the risk of prostate cancer among rotating-shift workers, International Journal of Urology, vol.17, issue.3, pp.206-211, 2011. ,
DOI : 10.1111/j.1442-2042.2010.02714.x
Night Work and the Risk of Cancer Among Men, American Journal of Epidemiology, vol.176, issue.9, pp.751-759, 2012. ,
DOI : 10.1093/aje/kws318
URL : https://hal.archives-ouvertes.fr/pasteur-01009351
Cancer incidence among male military and civil pilots and flight attendants: an analysis on published data, Toxicology and Industrial Health, vol.158, issue.1, pp.273-282, 2005. ,
DOI : 10.1191/0748233705th238oa
Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study, British Journal of Cancer, vol.73, issue.1, pp.176-178, 2008. ,
DOI : 10.1016/j.smrv.2003.10.002
Inflammation and cancer: back to Virchow? Lancet, pp.539-545, 2001. ,
Inflammatory Cells and Cancer, The Journal of Experimental Medicine, vol.54, issue.6, pp.23-26, 2001. ,
DOI : 10.1073/pnas.95.16.9325
Inflammation and cancer, Nature, vol.2, issue.6917, pp.860-867, 2002. ,
DOI : 10.1006/cyto.1996.0074
Proliferative Inflammatory Atrophy of the Prostate, The American Journal of Pathology, vol.155, issue.6, pp.1985-1992, 1999. ,
DOI : 10.1016/S0002-9440(10)65517-4
Inflammation, atrophy, and prostate carcinogenesis, Urologic Oncology: Seminars and Original Investigations, vol.25, issue.5, pp.398-400, 2007. ,
DOI : 10.1016/j.urolonc.2007.05.007
Inflammation in prostate carcinogenesis, Nature Reviews Cancer, vol.175, issue.4, pp.256-269, 2007. ,
DOI : 10.1038/nrc2090
Epidemiologic association between prostatitis and prostate cancer, Urology, vol.60, issue.1, pp.78-83, 2002. ,
DOI : 10.1016/S0090-4295(02)01637-0
Meta-Analysis of Measures of Sexual Activity and Prostate Cancer, Epidemiology, vol.13, issue.1, pp.72-79, 2002. ,
DOI : 10.1097/00001648-200201000-00012
Sexual behaviour, STDs and risks for prostate cancer, British Journal of Cancer, vol.82, issue.3, pp.718-725, 2000. ,
DOI : 10.1054/bjoc.1999.0986
Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer, The Prostate, vol.57, issue.2, pp.127-133, 1999. ,
DOI : 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H
Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer, Urology, vol.53, issue.1, pp.139-147, 1999. ,
DOI : 10.1016/S0090-4295(98)00455-5
Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis, Urology, vol.58, issue.6, pp.1008-1015, 2001. ,
DOI : 10.1016/S0090-4295(01)01405-4
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1, Nature Genetics, vol.30, issue.2, pp.181-184, 2002. ,
DOI : 10.1038/ng823
Implications for RNase L in Prostate Cancer Biology, Biochemistry, vol.42, issue.7, pp.1805-1812, 2003. ,
DOI : 10.1021/bi027147i
Genetic Polymorphisms of Interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and Risk of Prostate Cancer, Cancer Research, vol.66, issue.8, pp.4525-4530, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-3987
Aspirin and cancer risk: an updated quantitative review to 2005, Cancer Causes & Control, vol.13, issue.7, pp.871-888, 2006. ,
DOI : 10.1007/s10552-006-0033-7
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement, The Lancet Oncology, vol.10, issue.5, pp.501-507, 2009. ,
DOI : 10.1016/S1470-2045(09)70035-X
Aspirin and cancer risk: a quantitative review to 2011, Annals of Oncology, vol.23, issue.6, pp.1403-1415, 2012. ,
DOI : 10.1093/annonc/mds113
Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma, The Prostate, vol.73, issue.20, pp.73-78, 2000. ,
DOI : 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G
Cyclooxygenase-2 and prostate carcinogenesis, Cancer Letters, vol.191, issue.2, pp.125-135, 2003. ,
DOI : 10.1016/S0304-3835(02)00524-4
Arachidonic acid metabolism in benign and malignant prostatic tissuein vitro: Effects of fatty acids and cyclooxygenase inhibitors, International Journal of Cancer, vol.81, issue.2, pp.176-180, 1994. ,
DOI : 10.1002/ijc.2910570208
Cyclooxygenase-2 Selective Inhibitors and Prostate Cancer: What Is the Clinical Benefit?, Journal of Clinical Oncology, vol.24, issue.18, pp.2691-2693, 2006. ,
DOI : 10.1200/JCO.2006.05.9709
Inflammatory Pathogenesis of Prostate Cancer and Celecoxib, Journal of Clinical Oncology, vol.28, issue.12, pp.197-198, 2010. ,
DOI : 10.1200/JCO.2009.27.1098
Serum androgens and prostate cancer, Cancer Epidemiol Biomark Prev, vol.5, pp.621-625, 1996. ,
Hormones and Prostate Cancer: Where Do We Go From Here?, JNCI Journal of the National Cancer Institute, vol.88, issue.16, pp.1093-1095, 1996. ,
DOI : 10.1093/jnci/88.16.1093
Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies, British Journal of Cancer, vol.80, issue.7, pp.930-934, 1999. ,
DOI : 10.1038/sj.bjc.6690445
Androgen and prostate cancer: is the hypothesis dead? Cancer Epidemiol Biomark Prev, pp.2525-2530, 2008. ,
Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies, J Natl Cancer Inst, vol.100, pp.170-183, 2008. ,
Role of Hormonal and Other Factors in Human Prostate Cancer, Journal of Toxicology and Environmental Health, Part B, vol.13, issue.1, pp.242-259, 2008. ,
DOI : 10.1093/aje/kwh139
Androgenic alopecia is not useful as an indicator of men at high risk of prostate cancer, European Journal of Cancer, vol.46, issue.18, pp.3294-3299, 2010. ,
DOI : 10.1016/j.ejca.2010.05.020
Male infertility and prostate cancer risk: a nested case???control study, Cancer Causes & Control, vol.362, issue.10, pp.1635-1643, 2010. ,
DOI : 10.1007/s10552-010-9592-8
Male pattern baldness and prostate cancer risk in a population-based case???control study, Cancer Epidemiology, vol.34, issue.2, pp.131-135, 2010. ,
DOI : 10.1016/j.canep.2010.02.003
Male pattern baldness and the risk of prostate cancer, Annals of Oncology, vol.22, issue.8, pp.1824-1827, 2011. ,
DOI : 10.1093/annonc/mdq695
Prostate Cancer Risk and Serum Levels of Insulin and Leptin: a Population-Based Study, JNCI Journal of the National Cancer Institute, vol.93, issue.10, pp.783-789, 2001. ,
DOI : 10.1093/jnci/93.10.783
Insulin-like Growth Factors and Prostate Cancer, Epidemiologic Reviews, vol.23, issue.1, pp.59-66, 2001. ,
DOI : 10.1093/oxfordjournals.epirev.a000796
URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.581.5573
Metabolic syndrome and urologic diseases, Rev Urol, vol.12, pp.157-180, 2010. ,
The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study, BJU International, vol.66, issue.6, pp.929-935, 2011. ,
DOI : 10.1111/j.1464-410X.2010.09703.x
Metabolic syndrome: definitions and controversies, BMC Medicine, vol.163, issue.Suppl 3, p.48, 2011. ,
DOI : 10.1001/archinte.163.4.427
The Correlation Between Metabolic Syndrome and Prostatic Diseases, European Urology, vol.61, issue.3, pp.560-570, 2012. ,
DOI : 10.1016/j.eururo.2011.11.013
Obesity and cancer risk: evidence, mechanisms, and recommendations, Annals of the New York Academy of Sciences, vol.17, issue.1, pp.37-43, 2012. ,
DOI : 10.1111/j.1749-6632.2012.06750.x
Cholesterol and Cancer: Answers and New Questions, Cancer Epidemiology Biomarkers & Prevention, vol.18, issue.11, pp.2805-2806, 2009. ,
DOI : 10.1158/1055-9965.EPI-09-1027
Statin Use and Risk of Prostate Cancer: Results from a Population-based Epidemiologic Study, American Journal of Epidemiology, vol.168, issue.3, pp.250-260, 2008. ,
DOI : 10.1093/aje/kwn141
Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies, PLoS ONE, vol.7, issue.10, p.46691, 2012. ,
DOI : 10.1371/journal.pone.0046691.s001
Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial, Cancer Epidemiology Biomarkers & Prevention, vol.18, issue.11, pp.2807-2813, 2009. ,
DOI : 10.1158/1055-9965.EPI-09-0472
Mendelian inheritance of familial prostate cancer., Proceedings of the National Academy of Sciences, vol.89, issue.8, pp.3367-3371, 1992. ,
DOI : 10.1073/pnas.89.8.3367
Genetics of Prostate Cancer: Too Many Loci, Too Few Genes, The American Journal of Human Genetics, vol.67, issue.6, pp.1367-1375, 2000. ,
DOI : 10.1086/316916
Heterogeneity in genetic susceptibility to prostate cancer, European Journal of Internal Medicine, vol.12, issue.1, pp.11-16, 2001. ,
DOI : 10.1016/S0953-6205(00)00136-9
Inherited genotype and prostate cancer outcomes, Cancer Epidemiol Biomark Prev, vol.1110, issue.1, pp.945-952, 2002. ,
The complex genetic epidemiology of prostate cancer, Human Molecular Genetics, vol.13, issue.90001, pp.103-121, 2004. ,
DOI : 10.1093/hmg/ddh072
Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism, Cancer Detection and Prevention, vol.30, issue.5, pp.412-422, 2006. ,
DOI : 10.1016/j.cdp.2006.09.004
Does " clock " matter in prostate cancer? Cancer Epidemiol Biomark Prev, pp.3-5, 2006. ,
Weight of Evidence Evaluation of Potential Human Cancer Risks from Exposure to Polychlorinated Biphenyls: An Update Based on Studies Published Since 2003, Critical Reviews in Toxicology, vol.9, issue.17, pp.299-331, 2009. ,
DOI : 10.1210/me.2006-0007
Testing the Circadian Gene Hypothesis in Prostate Cancer: A Population-Based Case-Control Study, Cancer Research, vol.69, issue.24, pp.9315-9322, 2009. ,
DOI : 10.1158/0008-5472.CAN-09-0648
Correlation between Circadian Gene Variants and Serum Levels of Sex Steroids and Insulin-like Growth Factor-I, Cancer Epidemiology Biomarkers & Prevention, vol.17, issue.11, pp.3268-3273, 2008. ,
DOI : 10.1158/1055-9965.EPI-08-0073
ERSPC: features and preliminary results of France, BJU International, vol.13, issue.s2, pp.27-29, 2003. ,
DOI : 10.1111/j.1464-410X.2003.04392.x
Prostate-Cancer Mortality at 11 Years of Follow-up, New England Journal of Medicine, vol.366, issue.11, pp.981-990, 2012. ,
DOI : 10.1056/NEJMoa1113135
Integrative Epidemiology: From Risk Assessment to Outcome Prediction, Journal of Clinical Oncology, vol.23, issue.2, pp.267-275, 2005. ,
DOI : 10.1200/JCO.2005.05.122
Integrative Cancer Epidemiology--The Next Generation, Cancer Discovery, vol.2, issue.12, pp.1087-1090, 2012. ,
DOI : 10.1158/2159-8290.CD-12-0424